AOC3 and fibrosis: Similar to other CAMs, enzymatically cleaved VAP-1 fragments can be released from ECs, resulting in higher circulating levels of soluble VAP-1 in patients with fibrosis due to alcoholic liver disease, PBC and PSC when compared to normal controls or patients with rheumatoid arthritis or inflammatory bowel disease [33,172].